Table 2.
Comparison of demographics of patients receiving different treatments stratified by nomogram points
| Nomogram points | 3–4.2 (n = 241) | 6.7–10 (n = 545) | 11.9–13 (n = 301) | 15.2–18 (n = 230) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SR/Ablation/ TACE/ Transplant (n = 226) | Targeted/ Supportive (n = 15) | P | SR/Ablation/ TACE/ Transplant (n = 448) | Targeted/ Supportive (n = 97) | P | SR/Ablation/ TACE/ Transplant (n = 152) | Targeted/ Supportive (n = 149) | P | SR/Ablation/ TACE/ Transplant (n = 46) | Targeted/ Supportive (n = 184) | p | |
| Age | 67 ± 12 | 72 ± 10 | 0.173 | 65 ± 13 | 64 ± 15 | 0.878 | 64 ± 14 | 64 ± 15 | 0.296 | 59 ± 13 | 62 ± 13 | 0.113 |
| Male (%) | 166 (73) | 14 (93) | 0.124 | 340 (76) | 71 (73) | 0.576 | 117 (77) | 125 (84) | 0.131 | 36 (78) | 162 (88) | 0.086 |
| HBV (%) | 110 (49) | 4 (27) | 0.115 | 238 (53) | 55 (57) | 0.522 | 85 (56) | 87 (58) | 0.665 | 30 (65) | 112 (61) | 0.587 |
| HCV (%) | 81 (36) | 7 (47) | 0.399 | 130 (29) | 24 (25) | 0.397 | 27 (18) | 33 (22) | 0.341 | 10 (22) | 37 (20) | 0.806 |
| Alcoholism (%) | 47 (21) | 2 (13) | 0.742 | 99 (22) | 14 (14) | 0.091 | 41 (27) | 36 (24) | 0.576 | 12 (26) | 57 (31) | 0.517 |
| CTP class A (%) | 225 (100) | 14 (93) | 0.121 | 371 (83) | 83 (86) | 0.51 | 99 (65) | 117 (79) | 0.01 | 0 | 0 | N/A |
| Ascites (%) | 21 (9) | 2 (13) | 0.642 | 83 (19) | 20 (21) | 0.633 | 61 (40) | 48 (32) | 0.153 | 30 (65) | 133 (72) | 0.346 |
| eGFR > 60 (ml/min/1.73m2) | 173 (77) | 5 (33) | 0.001 | 338 (75) | 71 (73) | 0.642 | 114 (75) | 111 (75) | 0.92 | 37 (80) | 144 (78) | 0.747 |
| Tumor > 5 cm | 26 (12) | 6 (40) | 0.007 | 280 (63) | 75 (77) | 0.006 | 121 (80) | 135 (91) | 0.008 | 34 (74) | 160 (87) | 0.029 |
| Single tumor (%) | 167 (74) | 8 (53) | 0.084 | 278 (62) | 53 (55) | 0.175 | 73 (48) | 81 (54) | 0.272 | 23 (50) | 89 (48) | 0.843 |
| Tumor burden 0/1/2/3 | 16/69/14/0 | 13/40/47/0 | 0.008 | 4/12/50/34 | 3/8/27/62 | <.001 | 0/0/35/65 | 0/0/21/79 | 0.01 | 0/0/0/100 | 0/0/0/100 | N/A |
| Performance status 0/1/2 (%) | 17/64/19 | 47/33/20 | 0.014 | 35/47/18 | 66/21/13 | <.001 | 0/68/32 | 0/69/31 | 0.799 | 30/46/24 | 20/48/32 | 0.239 |
| Vascular invasion (%) | 0 | 0 | N/A | 136 (30) | 57 (59) | <.001 | 84 (55) | 107 (72) | 0.003 | 37 (80) | 170 (92) | 0.016 |
| Metastasis/lymph node (%) | 0 | 0 | N/A | 27 (6) | 15 (15) | 0.002 | 30 (20) | 47 (32) | 0.019 | 14 (30) | 65 (35) | 0.532 |
| AFP > 400 ng/mL | 33 (15) | 3 (20) | 0.475 | 137 (31) | 50 (52) | <.001 | 68 (45) | 92 (62) | 0.003 | 22 (48) | 115 (63) | 0.07 |
| Diabetes mellitus (%) | 76 (34) | 6 (40) | 0.614 | 112 (25) | 23 (24) | 0.79 | 47 (31) | 46 (31) | 0.993 | 10 (22) | 38 (21) | 0.871 |
SR surgical resection, TACE transarterial chemoembolization, CTP Child-Turcotte-Pugh, eGFR estimated glomerular filtration rate, HBV hepatitis B virus, HCV hepatitis C virus